Jeantine Lunshof is a philosopher and bioethicist. Since 1992, she has been involved in international research collaborations on ethical issues in human genetics. She holds affiliations with VU University, Department of Molecular Cell Physiology, Amsterdam (The Netherlands), and with CESAGEN (Lancaster, UK). Her current work focuses on ethical and public policy aspects of pharmacogenomics, personalized medicine, genome-wide association studies (GWAS) and on the philosophy of systems biology. Research interests also include the use of philosophical discourse practices in dealing with genomics' benchside questions. Jeantine has been an ethics consultant to the Personal Genome Project since early 2006. She is an Affiliate Member of the NIH Pharmacogenetics Research Network (PGRN) and a Member of the Public Population Project in Genomics (P3G) Consortium. She also is a member of the Editorial Board of Personalized Medicine.

Download full-text PDF

Source
http://dx.doi.org/10.2217/17410541.5.3.215DOI Listing

Publication Analysis

Top Keywords

personalized medicine
8
interview jeantine
4
jeantine lunshof
4
lunshof philosopher
4
philosopher bioethicist
4
bioethicist 1992
4
1992 involved
4
involved international
4
international collaborations
4
collaborations ethical
4

Similar Publications

Our previous studies revealed the existence of a Universal Receptive System that regulates interactions between cells and their environment. This system is composed of DNA- and RNA-based Teazeled receptors (TezRs) found on the surface of prokaryotic and eukaryotic cells, as well as integrases and recombinases. In the current study, we aimed to provide further insight into the regulatory role of TezR and its loss in Staphylococcus aureus gene transcription.

View Article and Find Full Text PDF

Objective: This study aimed to evaluate and compare the clinicopathologic features of primary fallopian tubal carcinoma (PFTC) and high-grade serous ovarian cancer (HGSOC) and explore the prognostic factors of these two malignant tumors.

Methods: Fifty-seven patients diagnosed with PFTC from 2006 to 2015 and 60 patients diagnosed with HGSOC from 2014 to 2015 with complete prognostic information were identified at Women's Hospital of Zhejiang University. The clinicopathological and surgical data were collected, and the survival of the patients was followed for 5 years after surgery.

View Article and Find Full Text PDF

Epigenetic modification regulates the ligamentum flavum hypertrophy through miR-335-3p/SERPINE2/β-catenin signaling pathway.

Cell Mol Biol Lett

January 2025

Department of Orthopaedics, Peking University Third Hospital, Peking University, No.49 NorthGarden Road, Haidian District, Beijing, 100191, Beijing, China.

Background: Epigenetic modifications have been proved to play important roles in the spinal degenerative diseases. As a type of noncoding RNA, the microRNA (miRNA) is a vital class of regulatory factor in the epigenetic modifications, while the role of miRNAs in the regulation of epigenetic modifications in ligamentum flavum hypertrophy (LFH) has not been fully investigated.

Methods: The miRNA sequencing analysis was used to explore the change of miRNA expression during the fibrosis of ligamentum flavum (LF) cells caused by the TGF-β1 (10 ng/ml).

View Article and Find Full Text PDF

Aging remains the foremost risk factor for cardiovascular and cerebrovascular diseases, surpassing traditional factors in epidemiological significance. This review elucidates the cellular and molecular mechanisms underlying vascular aging, with an emphasis on sex differences that influence disease progression and clinical outcomes in older adults. We discuss the convergence of aging processes at the macro- and microvascular levels and their contributions to the pathogenesis of vascular diseases.

View Article and Find Full Text PDF

Functionalization of polymer nanoparticles (NPs) with targeting peptides is of interest for drug delivery applications to enhance tumor accumulation and penetration. Herein, we evaluated the feasibility of two different methods for the attachment of a tumor-penetrating peptide LinTT1 (AKRGARSTA) to poly(ethylene glycol)-block-poly(ε-caprolactone) (PCL-PEG) NPs: (1) "post-conjugation" onto pre-formed nanoparticles, and (2) "pre-conjugation", the synthesis and purification of peptide-polymer conjugates and subsequent nanoprecipitation of the conjugates diluted with non-functionalized polymers. Conjugation of the labelled peptide via maleimide-thiol chemistry was verified by gel permeation chromatography (GPC) and fluorescence measurements.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!